2010
Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region
Taylor MJ, Sen S, Bhagwagar Z. Antidepressant Response and the Serotonin Transporter Gene-Linked Polymorphic Region. Biological Psychiatry 2010, 68: 536-543. PMID: 20615496, PMCID: PMC2929304, DOI: 10.1016/j.biopsych.2010.04.034.Peer-Reviewed Original Research
2004
Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?
Rabiner E, Bhagwagar Z, Gunn R, Cowen P, Grasby P. Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression? Neuropsychopharmacology 2004, 29: 1688-1698. PMID: 15127080, DOI: 10.1038/sj.npp.1300472.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAdultAutoreceptorsDepressive DisorderDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPhenotypePindololPiperazinesPsychiatric Status Rating ScalesPyridinesRadiopharmaceuticalsReceptor, Serotonin, 5-HT1ASerotonin AntagonistsTomography, Emission-ComputedInositol for depressive disorders
Taylor M, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. 2004, 2004: cd004049. PMID: 15106232, PMCID: PMC6984679, DOI: 10.1002/14651858.cd004049.pub2.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive DisorderHumansInositolRandomized Controlled Trials as TopicConceptsTreatment of depressionCochrane Controlled Trials RegisterControlled Trials RegisterTrials RegisterAdjunctive therapyDepressive disorderNeurosis Controlled Trials RegisterCochrane Collaboration DepressionAcceptability of treatmentDouble-blind designShort-term trialsAntidepressant medicationDATA COLLECTIONTherapeutic benefitAlternative treatmentReference listsAffective disordersEffective interventionsTerm trialsAdverse effectsTrialsPoor acceptabilityDepressionTreatmentDisorders
2003
Increase in Concentration of Waking Salivary Cortisol in Recovered Patients With Depression
Bhagwagar Z, Hafizi S, Cowen P. Increase in Concentration of Waking Salivary Cortisol in Recovered Patients With Depression. American Journal Of Psychiatry 2003, 160: 1890-1891. PMID: 14514508, DOI: 10.1176/appi.ajp.160.10.1890.Peer-Reviewed Original ResearchConceptsSalivary cortisol levelsCortisol levelsDepressed patientsAcute major depressionComorbid medical conditionsHPA axis abnormalitiesWithdrawal of medicationCoronary heart diseaseElevated plasma cortisol levelsHPA axis activityHealthy comparison subjectsPlasma cortisol levelsHealthy comparison groupClinical recoveryAxis abnormalitiesRecovered patientsAdrenal axisFurther episodesAxis activityHeart diseaseMajor depressionMedical conditionsComparison subjectsPatientsDepressed subjectsRisperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients.
Sharpley A, Bhagwagar Z, Hafizi S, Whale W, Gijsman H, Cowen P. Risperidone augmentation decreases rapid eye movement sleep and decreases wake in treatment-resistant depressed patients. The Journal Of Clinical Psychiatry 2003, 64: 192-6. PMID: 12633128, DOI: 10.4088/jcp.v64n0212.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAntidepressive AgentsAntipsychotic AgentsCross-Over StudiesDepressive DisorderDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMiddle AgedPersonality InventoryPlacebosPolysomnographyPsychiatric Status Rating ScalesRisperidoneSleep, REMTreatment OutcomeWakefulnessConceptsRapid eye movement (REM) sleepEye movement sleepDepressed patientsHealthy volunteersRisperidone treatmentMovement sleepREM sleepMedication-resistant depressed patientsTreatment-resistant depressed patientsConventional antidepressant medicationAntidepressant-like effectsAntipsychotic agent risperidoneDepression Rating ScaleMajor depressive disorderDSM-IV criteriaPatients meritRisperidone additionRisperidone augmentationAntidepressant medicationRisperidone administrationSingle doseTherapeutic dosesAugmentation agentsDepressive disorderHealthy subjects
2002
Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients
Bhagwagar Z, Hafizi S, Cowen P. Cortisol modulation of 5-HT-mediated growth hormone release in recovered depressed patients. Journal Of Affective Disorders 2002, 72: 249-255. PMID: 12450642, DOI: 10.1016/s0165-0327(01)00467-0.Peer-Reviewed Original ResearchConceptsGrowth hormone releaseDepressed patientsMajor depressionHormone releaseStress-induced cortisol secretionBrain serotonin functionPlasma GH levelsEffects of cortisolEffect of hydrocortisoneCross-over designStressful life eventsGH responseGH levelsSingle doseCortisol secretionGH releaseHealthy controlsSerotonin functionRecurrent depressionTRP infusionHealthy volunteersCortisol modulationDepressive symptomatologyDepressed subjectsEuthymic subjectsState and trait abnormalities in serotonin function in major depression
Bhagwagar Z, Whale R, Cowen P. State and trait abnormalities in serotonin function in major depression. The British Journal Of Psychiatry 2002, 180: 24-28. PMID: 11772847, DOI: 10.1192/bjp.180.1.24.Peer-Reviewed Original ResearchConceptsCortisol responseHealthy controlsMajor depressionSerotonin functionRecovered subjectsAdrenal axis dysfunctionBrain serotonin functionPlacebo-controlled designMarker of vulnerabilityAxis dysfunctionClinical recoveryReuptake inhibitorsUnmedicated subjectsProlactin responseDepressed patientsEndocrine responsesNeuroendocrine studiesDepressed subjectsCitalopramDepressionPatientsSubjectsResponseDysfunctionNeurotransmission
2001
Decreased sensitivity of 5-HT1D receptors in melancholic depression
Whale R, Clifford E, Bhagwagar Z, Cowen P. Decreased sensitivity of 5-HT1D receptors in melancholic depression. The British Journal Of Psychiatry 2001, 178: 454-457. PMID: 11331562, DOI: 10.1192/bjp.178.5.454.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsGrowth hormone responseGrowth hormone releaseSSRI treatmentMajor depressionHormone releaseMelancholic depressionHormone responseBrain serotonin functionSerotonin reuptake inhibitorsReuptake inhibitorsDepressive syndromeReceptor agonistReceptor subtypesSerotonin functionHealthy subjectsReceptor sensitivityPatientsControl groupMarked reductionZolmitriptanDepressionReceptorsTreatmentSelective ligands